DHA phase III small business innovation research prototype other transaction agreement for project titled, "broad spectrum snakebite antidote: conclusion of oral product development"
Active Other Transaction Agreement Awarded Last action
- Contract number
- HT94252590011
- Awardee
-
Ophirex, Inc. UEI W452WY5E2JQ9
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $29,999,425
Award facts
- Contract value 100% obligated
- $29,999,425.00 Current and potential, with all options
- Completion date 81% complete
- Current and potential, with all options
- NAICS code
- Not on record
- Competition
- Competed Broad Agency Announcement
- Pricing
- Other
- Place of performance
- Corte Madera, CA 94925, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $10,815,358 | |
| Funding Only Action | $12,181,539 | |
| Funding Only Action | -$3,084,480 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | -$5,721,986 | |
| Original award | $15,808,994 |
About this award
The Defense Health Agency awarded an Other Transaction Agreement to Ophirex, Inc., a small business, on May 5, 2025, with a ceiling value of $29,999,425 for Phase III development of a broad-spectrum snakebite antidote in oral formulation. This OTA sits outside the FAR and represents the concluding phase of the company's SBIR-funded effort to develop varespladib, a phospholipase A2 inhibitor targeting snake venom toxins.
The agreement runs through March 4, 2027. Work is performed at Ophirex's facility in Corte Madera, California. The oral product development effort builds on prior DHA and Army Medical Command SBIR phases and complements parallel development of an intravenous formulation supported by FDA grant funding. Varespladib is designed to improve recovery outcomes and reduce complications in snakebite envenomation cases, addressing limitations of conventional antivenom treatments.
Quick answers
Who was awarded contract HT94252590011?
HT94252590011 was awarded to Ophirex, Inc. by Defense Health Agency (Department of Defense) on May 5, 2025.
How much is contract HT94252590011 worth?
The government has obligated $29,999,425 on HT94252590011.
Was contract HT94252590011 competed?
The extent of competition for HT94252590011 was competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award